Rotavirus Gastroenteritis
Conditions
Brief summary
An open label study to evaluate immunogenicity, safety, and reactogenicity of Rotavac® (live attenuated oral rotavirus vaccine) as a 3-dose series in healthy infants aged between 6 weeks and 8 weeks in Vietnam
Detailed description
* The study is an open labeled, clinical trial in infants 6-8 weeks of age will be assigned to receive 3 doses of Rotavac® to evaluate the immunogenicity and safety. * Active surveillance will be conducted for all participants for 14 & 28 days after each dose of vaccine to obtain information on adverse events. (Reactogenicity) * Childhood vaccines including pentavalent (Diptheria, Tetanus, Pertussis, Hib, Hepatitis B) and oral polio vaccine as well as injectable polio vaccine will be administered along with the study vaccines as per Expanded Program on Immunization (EPI) * Safety assessments will include observation in the study clinic for 30 minutes after each vaccine administration to record immediate adverse events. A subject diary card and personal contact with the subjects will be made to record adverse events during the 14-day period following vaccine administration.
Interventions
BIOLOGICALRotavac
Rotavac Is a monovalent vaccine containing suspension of live attenuated rotavirus 116E strain, a naturally occurring reassortant strain G9P\[11\], containing one bovine rotavirus gene P\[11\] and 10 human rotavirus genes prepared in Vero cells administered orally at 6, 10 and 14 weeks of age.
Sponsors
Bharat Biotech International Limited
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
6 Weeks to 8 Weeks
Healthy volunteers
Yes
Inclusion criteria
1. Healthy infants as established by medical history and clinical examination 2. Age: 6-8 weeks 3. Weight ≥2.5kgs at birth 4. Infants receiving EPI vaccines as per Vietnam immunization program 5. Parental ability and willingness to provide informed consent. 6. Parent who intends to remain in the area with the participant during the study period.
Exclusion criteria
1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment (temporary exclusion). 2. Presence of fever (\>37.5C) or hypothermia (\<35.5C) on the day of enrollment (temporary exclusion). 3. Concurrent participation in another clinical trial. 4. Presence of significant malnutrition or any systemic disorder (cardiovascular, pulmonary, hepatic, renal, gastrointestinal, haematological, endocrine, immuno-logical, dermatological, neurological, cancer or autoimmune disease) as determined by medical history and/or physical examination which would compromise the child's health or is likely to result in non-conformance to the protocol. 5. History of congenital abdominal disorders, intussusception, abdominal surgery 6. Known or suspected impairment of immunological function based on medical history and physical examination. 7. Prior receipt of rotavirus vaccine. 8. A known sensitivity or allergy to any components of the study vaccines. 9. Major congenital or genetic defect. 10. Participant's parents not able, available or willing to accept active follow-up by the study staff. 11. Has received any immunoglobulin therapy and/or blood products since birth or planned administration during the study period. 12. History of chronic administration (defined as more than 14 days) of immunosuppressant including corticosteroids. Infants on inhaled or topical steroids may be permitted to participate in the study. 13. History of any neurologic disorders or seizures. 14. Any medical condition in the parents/ infants that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parent's/legally acceptable representative's ability to give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Demonstrate immunogenicity of 3-dose regimen of Rotavac | At the end of 28 days after last dose | Immunogenicity of 3-dose regimen of Rotavac with respect to geometric mean titres (GMT) of serum anti-rotavirus IgA at baseline and post-vaccination 4-6 weeks after third dose |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Assess and compare reactogenicity and safety (adverse events) | At the end of 28 days after last dose | Reactogenicity and safety of Rotavac in terms of adverse event |
Countries
Vietnam
Outcome results
None listed